Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deep China Price Cuts Reveal Complex Considerations

This article was originally published in PharmAsia News

Executive Summary

Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.


Related Content

2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
What’s Separating The Growers And No-Growers In China?
AstraZeneca Upbeat On China Prospects For New Products
Where Is The Reward? New Drug Developers See Red In China
Count Me In! China To Update Drug Coverage After Long Wait
China Growth Rebounds But Pharma Starts Cutting Prices
GSK Foresees Return To Emerging Markets Growth
China Approves First HPV Vaccine But Can GSK Secure Its Lead?


Related Companies